ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY', Kidney International Reports, 8, pp. S350 - S350, http://dx.doi.org/10.1016/j.ekir.2023.02.786
,2023, 'WCN23-1085 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY', Kidney International Reports, 8, pp. S279 - S280, http://dx.doi.org/10.1016/j.ekir.2023.02.630
,2022, 'Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program', Diabetes, Obesity and Metabolism, 24, pp. 2459 - 2464, http://dx.doi.org/10.1111/dom.14832
,2022, 'Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial', Trials, 23, pp. 361, http://dx.doi.org/10.1186/s13063-022-06167-2
,2022, 'Digital health technologies to support medication adherence in chronic kidney disease', Nephrology, 27, pp. 917 - 924, http://dx.doi.org/10.1111/nep.14113
,2022, 'Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID): A multi-center, multinational validation study to assess the accuracy and feasibility of measuring vascular access function in clinical practice', BMC Nephrology, 23, http://dx.doi.org/10.1186/s12882-022-02987-1
,2022, 'Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials', The Lancet, 400, pp. 1788 - 1801, http://dx.doi.org/10.1016/S0140-6736(22)02074-8
,2022, 'Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria', Journal of the American College of Cardiology, 80, pp. 1721 - 1731, http://dx.doi.org/10.1016/j.jacc.2022.08.772
,2022, 'Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial', Journal of the American Heart Association, 11, pp. e025045, http://dx.doi.org/10.1161/JAHA.121.025045
,2022, 'SGLT2 inhibitors and finerenone: one or the other or both?', Nephrology Dialysis Transplantation, 37, pp. 1209 - 1211, http://dx.doi.org/10.1093/ndt/gfac046
,2022, 'The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial', Diabetes and Metabolism, 48, pp. 101331, http://dx.doi.org/10.1016/j.diabet.2022.101331
,2022, 'Sex differences in chronic kidney disease prevalence in Asia: A systematic review and meta-analysis', Clinical Kidney Journal, 15, pp. 1144 - 1151, http://dx.doi.org/10.1093/ckj/sfac030
,2022, 'Trimming the fat: Is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review', Clinical Kidney Journal, 15, pp. 1049 - 1059, http://dx.doi.org/10.1093/ckj/sfab288
,2022, 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 327, pp. 1888 - 1898, http://dx.doi.org/10.1001/jama.2022.5368
,2022, 'Risk factors for incident kidney disease in older adults: an Australian prospective population-based study', Internal Medicine Journal, 52, pp. 808 - 817, http://dx.doi.org/10.1111/imj.15074
,2022, 'A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation', Frontiers in Cardiovascular Medicine, 9, http://dx.doi.org/10.3389/fcvm.2022.840611
,2022, 'Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice', International Journal of Cardiology, 352, pp. 172 - 179, http://dx.doi.org/10.1016/j.ijcard.2022.01.042
,2022, 'Digital health and artificial intelligence in kidney research: A report from the 2020 Kidney Disease Clinical Trialists (KDCT) meeting', Nephrology Dialysis Transplantation, 37, pp. 620 - 627, http://dx.doi.org/10.1093/ndt/gfab320
,2022, 'Premature Death in Kidney Transplant Recipients: The Time for Trials is Now', Journal of the American Society of Nephrology, 33, pp. 665 - 673, http://dx.doi.org/10.1681/ASN.2021111517
,2022, 'SGLT2 inhibitors may prevent diabetes', Nature Reviews Nephrology, 18, pp. 203 - 204, http://dx.doi.org/10.1038/s41581-022-00541-8
,2022, 'Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction', Frontiers in Pharmacology, 13, http://dx.doi.org/10.3389/fphar.2022.834898
,2022, 'Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial', Clinical Journal of the American Society of Nephrology, 17, pp. 361 - 373, http://dx.doi.org/10.2215/CJN.08980621
,2022, 'Antiplatelet agents for chronic kidney disease', Cochrane Database of Systematic Reviews, 2022, http://dx.doi.org/10.1002/14651858.CD008834.pub4
,2022, 'Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial', American Journal of Kidney Diseases, 79, pp. 244 - 256.e1, http://dx.doi.org/10.1053/j.ajkd.2021.05.005
,2022, 'GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes', Kidney International, 101, pp. 360 - 368, http://dx.doi.org/10.1016/j.kint.2021.10.033
,2022, 'Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial', BMJ, 379, pp. e072175, http://dx.doi.org/10.1136/bmj-2022-072175
,2022, 'Can Peer Review Be Kinder? Supportive Peer Review: A Re-Commitment to Kindness and a Call to Action', Canadian Journal of Kidney Health and Disease, 9, http://dx.doi.org/10.1177/20543581221080327
,2022, 'Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study', Canadian Journal of Kidney Health and Disease, 9, http://dx.doi.org/10.1177/20543581221145068
,2022, 'Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial', Journal of Diabetes Investigation, 13, pp. 54 - 64, http://dx.doi.org/10.1111/jdi.13624
,2022, 'Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial', Journal of Diabetes Research, 2022, http://dx.doi.org/10.1155/2022/9998891
,2022, 'INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL', Journal of the American College of Cardiology, 79, pp. 299 - 299, http://dx.doi.org/10.1016/s0735-1097(22)01290-6
,2021, 'Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial', European Heart Journal, 42, pp. 4891 - 4901, http://dx.doi.org/10.1093/eurheartj/ehab497
,2021, 'Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial', Trials, 22, pp. 573, http://dx.doi.org/10.1186/s13063-021-05521-0
,2021, 'Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis', Diabetes, Obesity and Metabolism, 23, pp. 2707 - 2715, http://dx.doi.org/10.1111/dom.14525
,2021, 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics', American Journal of Nephrology, 52, pp. 827 - 836, http://dx.doi.org/10.1159/000519812
,2021, 'Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', European Heart Journal, 42, pp. ehab724.2647, http://dx.doi.org/10.1093/eurheartj/ehab724.2647
,2021, 'Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1365 - 1375, http://dx.doi.org/10.2215/CJN.17151120
,2021, 'Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program', Endocrinology, Diabetes and Metabolism, 4, pp. e00247, http://dx.doi.org/10.1002/edm2.247
,2021, 'Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis', Hemodialysis International, 25, pp. 322 - 332, http://dx.doi.org/10.1111/hdi.12924
,2021, 'Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE', DIABETES, 70, http://dx.doi.org/10.2337/db21-133-LB
,2021, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-129-LB
,2021, 'The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-131-LB
,2021, 'Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial', Diabetes, Obesity and Metabolism, 23, pp. 1420 - 1425, http://dx.doi.org/10.1111/dom.14351
,2021, 'Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial', Circulation, 143, pp. 1735 - 1749, http://dx.doi.org/10.1161/CIRCULATIONAHA.120.048740
,2021, 'Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis', Stroke, 52, pp. 1545 - 1556, http://dx.doi.org/10.1161/STROKEAHA.120.031623
,2021, 'Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program', ESC Heart Failure, 8, pp. 1482 - 1493, http://dx.doi.org/10.1002/ehf2.13236
,2021, 'In response', Annals of Internal Medicine, 174, pp. 580, http://dx.doi.org/10.7326/L21-0091
,2021, 'Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice', Kidney International, 99, pp. 999 - 1009, http://dx.doi.org/10.1016/j.kint.2020.10.042
,2021, 'Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis', Kidney International Reports, 6, pp. 1058 - 1065, http://dx.doi.org/10.1016/j.ekir.2021.01.020
,